S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
S&P 500   3,123.95 (+0.06%)
DOW   27,957.38 (-0.28%)
QQQ   203.60 (+0.26%)
CGC   15.37 (+8.09%)
BABA   184.17 (-0.24%)
GE   11.48 (+0.35%)
T   38.14 (-3.78%)
ACB   2.40 (+5.25%)
F   8.89 (-0.67%)
PRI   132.20 (+0.84%)
BAC   32.94 (-0.06%)
DIS   148.55 (+0.61%)
Log in

Cara Therapeutics Price Target & Analyst Ratings (NASDAQ:CARA)

$22.42
+1.25 (+5.90 %)
(As of 11/19/2019 03:14 PM ET)
Today's Range
$21.24
Now: $22.42
$22.42
50-Day Range
$17.76
MA: $19.84
$21.60
52-Week Range
$12.19
Now: $22.42
$27.55
Volume28,819 shs
Average Volume374,347 shs
Market Capitalization$897.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23

Analyst Ratings

Cara Therapeutics (NASDAQ:CARA) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Cara Therapeutics in the last 12 months. Their average twelve-month price target is $26.92, suggesting that the stock has a possible upside of 20.07%. The high price target for CARA is $39.00 and the low price target for CARA is $13.36. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.882.892.892.90
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.92$26.93$26.93$24.74
Price Target Upside: 20.07% upside39.24% upside15.23% upside57.96% upside

Cara Therapeutics (NASDAQ:CARA) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cara Therapeutics (NASDAQ:CARA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/17/2019Needham & Company LLCReiterated RatingBuy$35.00Low
8/12/2019HC WainwrightReiterated RatingBuy ➝ Buy$31.00 ➝ $30.00Low
7/30/2019Piper Jaffray CompaniesBoost Price TargetOverweight$35.00 ➝ $39.00Medium
5/29/2019LaidlawBoost Price TargetBuy$26.00 ➝ $32.00Low
2/6/2019Jefferies Financial GroupInitiated CoverageBuy$22.00Low
1/15/2019Bank of AmericaInitiated CoverageNeutral$19.00Low
12/20/2018Canaccord GenuitySet Price TargetBuy$25.00Low
12/20/2018Janney Montgomery ScottInitiated CoverageBuy$27.00 ➝ $13.36High
11/7/2018Cantor FitzgeraldSet Price TargetBuy$27.00High
8/8/2018Stifel NicolausBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.00High
3/16/2018Seaport Global SecuritiesReiterated RatingBuyLow
(Data available from 11/19/2017 forward)
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Featured Article: What Are Treasury Bonds?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel